PolyMVA
Phase 1Small molecule
PolyMVA is one of 20 small molecule programs targeting Fatigue. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Astrocytoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Bicnu
MMelissa K Accordino
Approved
Voranigo
SServier
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Nexavar
BayerPhase 2
Beyfortus
BeiGenePhase 2
Avastin
BBio-Thera Solutions
Phase 2
Levulan
BBiomed Industries, Inc.
Phase 2
Radiotherapy
GSKPhase 3
Cialis
Eli LillyPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PolyMVA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Missouri-Columbia